Larotinib

CAS No. 1438072-11-7

Larotinib( —— )

Catalog No. M36515 CAS No. 1438072-11-7

Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 170 In Stock
10MG 258 In Stock
25MG 440 In Stock
50MG 616 In Stock
100MG 863 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Larotinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
  • Description
    Larotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Tyrosine Kinase
  • Target
    BTK
  • Recptor
    BTK | Tyrosine Kinases | IRAK | EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1438072-11-7
  • Formula Weight
    488.94
  • Molecular Formula
    C24H26ClFN4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C=1C2=C(C=C(OC)C(OCCCN3C[C@@]4([C@](C3)(OCCO4)[H])[H])=C2)N=CN1)C5=CC(Cl)=C(F)C=C5
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.?
molnova catalog
related products
  • QL-47

    A potent, selective, and irreversible BTK inhibitor with IC50 of 7 nM.

  • Atuzabrutinib

    Atuzabrutinib (SAR 444727) is a selective Bruton's tyrosine kinase (Btk) inhibitor that inhibits intra-neutrophilic neutrophilic granulocytes through inhibition of the adhesion receptor signaling pathway, and can be used to study autoimmune disorders such as arthritis in rheumatoid rodents and pemphigus vulgaris.

  • BTK-IN-23

    BTK-IN-23 is a highly potent and selective Btk inhibitor with IC50 of 3 nM.